Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Raises Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 1.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 356,730 shares of the medical research company’s stock after buying an additional 5,807 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.19% of IQVIA worth $82,479,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. UMB Bank N A MO purchased a new position in shares of IQVIA in the 4th quarter worth $26,000. Dividend Assets Capital LLC purchased a new position in shares of IQVIA in the 1st quarter worth $27,000. Johnson Financial Group Inc. purchased a new position in shares of IQVIA in the 4th quarter worth $34,000. Catalyst Capital Advisors LLC purchased a new position in shares of IQVIA in the 4th quarter worth $38,000. Finally, Amplius Wealth Advisors LLC purchased a new position in shares of IQVIA in the 4th quarter worth $45,000. 87.12% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:IQV traded up $6.30 during trading hours on Thursday, hitting $208.04. The company’s stock had a trading volume of 4,394 shares, compared to its average volume of 1,002,427. IQVIA Holdings Inc. has a 52 week low of $194.67 and a 52 week high of $285.61. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.93 and a quick ratio of 0.93. The company has a market capitalization of $39.38 billion, a price-to-earnings ratio of 36.35, a P/E/G ratio of 1.42 and a beta of 1.41. The firm’s fifty day moving average price is $213.11 and its 200 day moving average price is $233.86.

IQVIA (NYSE:IQVGet Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.27 by $0.07. IQVIA had a net margin of 7.69% and a return on equity of 28.80%. The business had revenue of $3.57 billion during the quarter, compared to analyst estimates of $3.54 billion. During the same quarter in the previous year, the business posted $2.05 EPS. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts predict that IQVIA Holdings Inc. will post 9.48 earnings per share for the current fiscal year.

IQV has been the subject of a number of recent research reports. Mizuho dropped their price objective on shares of IQVIA from $300.00 to $270.00 and set a “buy” rating for the company in a research note on Monday, March 7th. Wells Fargo & Company cut shares of IQVIA from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $290.00 to $235.00 in a research note on Monday, April 25th. Guggenheim assumed coverage on shares of IQVIA in a research note on Monday, May 23rd. They set a “buy” rating and a $244.00 price target for the company. Barclays dropped their price target on shares of IQVIA from $275.00 to $240.00 in a research note on Thursday, April 28th. Finally, Piper Sandler raised shares of IQVIA from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $231.00 to $255.00 in a research note on Thursday, April 28th. Two research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $277.80.

About IQVIA (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.